NEW YORK (GenomeWeb News) – Investment firm ISI Group today downgraded shares of Cepheid to Sell, saying it expects the Sunnyvale, Calif. molecular diagnostics firm's base business to slow due to increased competition in the hospital-acquired infection space.

In a research note, analyst Vijay Kumar put Cepheid's price target at $34 per share and outlined three factors that he expects to constrain the company's growth in the medium term. They include competition in the HAI space; limited upside to the company's new products; and pricing pressures and higher cost of goods sold.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Heads of various research funding agencies discuss how to encourage scientific breakthroughs, ScienceInsider reports.

The Kansas City Star examines issues surrounding newborn genome sequencing.

Researchers say their Research Resource Identifier citation format is catching on, Nature News reports.

In Science this week: the Human Silencing Hub protein complex, and more.